Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
By Reiji Anasako While suffering an uphill struggle at home, Japan drug makers enjoy robust revenues from their global brands, with their major products driving their earnings with double-digit growth. They will likely carry on this momentum this fiscal year,…
To read the full story
Related Article
- FY2017 Earnings Roundup - 4: Japan Makers Struggling to Recoup R&D Investments, New Value-Generating Model Is a Must
June 8, 2018
- FY2017 Earnings Roundup - 3: Top 3 Japan Generic Makers Pursuing Diversified Overseas Strategies
June 7, 2018
- FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
June 4, 2018
BUSINESS
- Drug Makers, Wholesalers See No Major Disruptions after Aomori Quake
December 10, 2025
- SanBio Clears Hurdle for Akuugo Shipments, Heads to Reimbursement Talks
December 10, 2025
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
- LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
- Kazuo Nakamura, Founder of Japan’s First CRO, Dies at 78
December 9, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…